(Q42262252)

English

Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial

scientific article published on 2 February 2017

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial (English)

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

phase III clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

quality of life

1 reference

based on heuristic

inferred from title

16

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

Caroline Robert

9

object named as

Caroline Robert

0 references

Virginia Ferraresi

object named as

Virginia Ferraresi

13

0 references

Paolo Antonio Ascierto

10

object named as

Paolo A Ascierto

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

Andrew Bottomley

17

object named as

Andrew Bottomley

1 reference

Europe PubMed Central

19 October 2017

PMC publication ID

Alexander Eggermont

21

object named as

Alexander M M Eggermont

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

Jedd D. Wolchok

6

object named as

Jedd D Wolchok

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

2

object named as

Stefan Suciu

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

Reinhard Dummer

5

object named as

Reinhard Dummer

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

author name string

Corneel Coens

1

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

Vanna Chiarion-Sileni

3

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

Jean-Jacques Grob

4

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

Henrik Schmidt

7

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

Omid Hamid

8

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

Jon M Richards

11

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

Celeste Lebbé

12

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

Michael Smylie

14

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

Jeffrey S Weber

15

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

Srividya Kotapati

18

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

Veerle de Pril

19

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

Alessandro Testori

20

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

publication date

2 February 2017

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

18

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

3

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

393-403

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5636622

26 October 2017

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5636622

26 October 2017

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5636622

26 October 2017

Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5636622

26 October 2017

Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5636622

26 October 2017

The prognostic significance of sentinel node tumour burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5636622

26 October 2017

Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5636622

26 October 2017

Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5636622

26 October 2017

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5636622

26 October 2017

Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5636622

26 October 2017

Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5636622

26 October 2017

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5636622

26 October 2017

Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5636622

26 October 2017

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5636622

26 October 2017

Final version of 2009 AJCC melanoma staging and classification

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5636622

26 October 2017

International perspective on health-related quality-of-life research in cancer clinical trials: the European Organisation for Research and Treatment of Cancer experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5636622

26 October 2017

Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials--does HRQOL evaluation in prostate cancer research inform clinical decision making?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5636622

26 October 2017

The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5636622

26 October 2017

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5636622

26 October 2017

Analysis of serial measurements in medical research

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5636622

26 October 2017

Interpreting the significance of changes in health-related quality-of-life scores.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5636622

29 May 2018

Health-related quality of life, fatigue, and depression under low-dose IFN-α therapy in melanoma patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5636622

17 August 2018

Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5636622

17 August 2018

Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5636622

17 August 2018

Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5636622

17 August 2018

Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of C

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5636622

17 August 2018

Cutaneous melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5636622

3 November 2018

Identifiers

10.1016/S1470-2045(17)30015-3

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

release_ue26kmqkazdg5lfwgxrh5ckuka

1 reference

https://api.fatcat.wiki/v0/release/ue26kmqkazdg5lfwgxrh5ckuka

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42262252&oldid=1940400758"